Stocks in Focus

KOLMAR KOREA Jumps Over 20% on Surprise Second-Quarter Earnings [Stock Spotlight]

PARK MIN
2026-08-12 10:00:34
[Edaily Reporter PARK MIN ] KOLMAR KOREA(161890)is surging by more than 20% in early trading on the 12th after announcing record-breaking quarterly earnings for the second quarter of this year.

According to MP Doctor, as of 9:56 a.m. today, KOLMAR KOREA is trading at 132,000 won, up 22.34% from the previous close. This is attributed to buying pressure driven by the company’s second-quarter “earnings surprise.”

Today, KOLMAR KOREA announced that its consolidated operating profit for the second quarter rose 50.17% year-over-year to 110,341 million won, while revenue increased 17.85% to 861,277 million won. Both revenue and operating profit represent all-time highs on a quarterly basis.

The expansion of global sales channels for indie brands, driven by the K-Beauty boom, is cited as the reason behind KOLMAR KOREA’s strong performance. A KOLMAR KOREA official stated, “Orders increased, particularly for skincare and suncare products, due to the expansion of indie brands’ global presence and the peak season effect for suncare products,” adding, “With the continued launch of new products by our global clients, we recorded our highest-ever quarterly results.”

Economy

Corporation

IT·Science

Economy

LG Corp. to Develop Skeleton and Ice Hockey Prospects… Also Extends Sponsorship of National Teams

LG Corp. is set to identify and nurture promising athletes in skeleton and ice hockey. The company is also extending its sponsorship of the national teams through 2030, continuing its long-term suppor…
2026-08-13 10:00:06

Corporation

CJ CheilJedang Corp.’s Rice Vinegar Reaches Annual Sales of 150 Billion Won in Japan… Expanding into Everyday Beverages

CJ CheilJedang Corp(097950)’s fruit-fermented vinegar brand “Micho (美酢)” is expanding its reach in Japan beyond vinegar consumed for health and beauty purposes to become a “daily wellness drink” enjoy…
2026-08-13 09:43:50

IT·Science

D&D Pharmatech Inc. to Take the Stage at 'K-Bio Deal Summit 2026' with a Full-Cycle Treatment Solution for MASH

D&D Pharmatech Inc.(347850)’s new drug development strategy—which addresses the entire progression of the disease, from the early stages of macrophage-associated steatohepatitis (MASH) to liver fibros…
2026-08-13 10:01:03